Barclays analyst Matt Miksic lowered the firm’s price target on Boston Scientific (BSX) to $96 from $100 and keeps an Overweight rating on the shares. The firm cites the company’s reduced 2026 outlook for the target cut. However, with expectations reset, attractive end markets, and share buybacks coming, Boston Scientific will “significantly outperform” over the next year, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Balances Strong Q1 With Softer Outlook
- Boston Scientific price target lowered to $84 from $87 at Goldman Sachs
- Boston Scientific: Sustained Outperformance and Solid Growth Support Buy Rating Despite Trimmed Target
- Why Is the SPY ETF Up Today, 4/22/2026?
- Boston Scientific: Proactive Guidance Reset and Resilient Growth Support Buy Rating Despite Lowered Target